[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytomegalovirus-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytomegalovirus-disease":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636743",false,"NCT07569653","Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.","A Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Letermovir Prophylaxis Duration Guided by Dynamic Monitoring of Specific T-cells for Preventing Cytomegalovirus Infection in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation in China.","Inclusion Criteria:\n\n1. Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n2. CMV serostatus of the recipient is positive (R+).\n3. Aged 18 years or older.\n4. Expected survival \\> 6 months.\n5. Provision of signed informed consent.\n\nExclusion Criteria:\n\n* 1.Active CMV infection or CMV disease at the time of screening.\n\n  2.Known hypersensitivity to Letermovir or its excipients.\n\n  3.Severe hepatic or renal impairment.\n\n  4.Pregnant or breastfeeding women.","ALL","18 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus \\[CMV\\] infection) based on the recovery of the patient's own immune system.\n\nCytomegalovirus (CMV) is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, Letermovir is typically given as a standard prevention for about 100 days post-transplant. However, some patients may recover their CMV-specific immunity earlier, while others may need longer protection.\n\nIn this study, researchers will use a dynamic monitoring technology (QuantiFERON-CMV) to detect the level of CMV-specific T-cells in patients. Participants will be randomly assigned to either the experimental group or the control group:\n\nExperimental Group: Letermovir discontinuation will be guided by T-cell recovery. If the test shows that the patient's CMV-specific T-cells have recovered, Letermovir may be stopped earlier than the standard 100 days.\n\nControl Group: Patients will receive the standard Letermovir prophylaxis for approximately 100 days, regardless of T-cell status.\n\nThe study aims to determine if this immune-guided strategy can effectively prevent CMV infection while potentially reducing the duration of medication and associated costs, without increasing the risk of CMV disease.",[25,26,27,28],"Cytomegalovirus Infections","Cytomegalovirus Disease","Hematopoietic Stem Cell Transplantation","Graft vs Host Disease","RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":33},"2025-10-30",{"date":37,"type":19},"2027-12",{"name":39,"class":40},"WeiShi","OTHER",12,""]